Research area · week to 3 Oct 2026

Hepatitis B Virus Studies

Moving in Journal of hepatology.

Moved this week: 1

Rebuilt 3 October 2026 at 3:19 pm AEST

Moved this week

Everything that moved →

144 Weeks of bulevirtide monotherapy for chronic hepatitis D: Final and post-treatment results from a phase III randomized trial.
Journal of hepatology · 1 Sept 2026 · Randomized Controlled Trial
Read the brief in JClub
- Open access
- 8 cites
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/41966308
Open in JClub

Latest in Hepatitis B Virus Studies

Newest first · last 60 days

From viral clearance to cancer prevention: the next phase of hepatitis elimination.
The lancet. Gastroenterology & hepatology · 1 Oct 2026 · Letter
Read the brief in JClub
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42685730
Open in JClub
Launch of the Africa CDC toolkit for hepatitis B: bringing care closer to people in Africa.
The lancet. Gastroenterology & hepatology · 1 Oct 2026 · Journal Article
Read the brief in JClub
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42508446
Open in JClub
WHO global hepatitis report 2026: guiding global action for elimination.
The lancet. Gastroenterology & hepatology · 1 Oct 2026 · Journal Article
Read the brief in JClub
- 1 cites
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42508445
Open in JClub
Sustained safety and efficacy of entecavir monotherapy for chronic hepatitis B after liver transplantation: 15-year follow-up.
Gastroenterology · 21 Sept 2026 · Journal Article
Read the brief in JClub
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42767282
Open in JClub
High rates of transition to immune active disease in a cohort of strictly defined immune tolerant patients with chronic hepatitis B: results from the RADICAL consortium.
Gut · 18 Sept 2026 · Journal Article
Over 50% of strictly defined immune tolerant chronic hepatitis B patients transition to immune active disease within five years, especially those with high-normal ALT levels.
- Open access
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42760116
Open in JClub
Occult hepatitis B virus infection.
Nature reviews. Gastroenterology & hepatology · 14 Sept 2026 · Review
Occult hepatitis B virus infection affects over 40% of individuals with isolated anti-HBc, posing significant transmission and reactivation risks.
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42736448
Open in JClub
HBsAg decline and clearance with peg-IFN therapy added to nucleos(t)ide analogues: an individual participant data meta-analysis of prospective trials (PROSPER).
Gut · 7 Sept 2026 · Meta-Analysis
Adding peg-IFN to nucleos(t)ide analogue therapy achieves HBsAg loss in up to 38% of chronic hepatitis B patients with low initial HBsAg levels.
- Open access
- 5 cites
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/41198171
Open in JClub
Characterisation of plasmablast-derived HBsAg-specific antibody and its structural basis for binding to native HBsAg dimer.
Gut · 7 Sept 2026 · Journal Article
Read the brief in JClub
- Open access
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/41663152
Open in JClub
PEG is back: revisiting the role of pegylated interferon alfa and benchmarking its place in HBV cure strategies.
Gut · 7 Sept 2026 · Journal Article
Read the brief in JClub
- 2 cites
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/41494801
Open in JClub
Nucleos(t)ide analogue therapy for EASL immune-tolerant phase hepatitis B.
Gut · 7 Sept 2026 · Letter
Read the brief in JClub
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/41339058
Open in JClub
Partial cure of chronic hepatitis B: potential implications for HCC surveillance?
Gut · 7 Sept 2026 · Journal Article
Read the brief in JClub
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/40730457
Open in JClub
Post-Transplant Hepatitis D Breakthrough Driven by Integrant-Derived HBsAg from an Extrahepatic HCC Metastasis.
Journal of hepatology · 5 Sept 2026 · Letter
Read the brief in JClub
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42700820
Open in JClub
Silent but persistent: Failure of continuous tenofovir based ART to prevent HBV and HDV reactivation under chemotherapy in an HBsAg-negative patient living with HIV.
Journal of hepatology · 2 Sept 2026 · Letter
Read the brief in JClub
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42685983
Open in JClub
Precision adherence support for hepatitis C treatment.
Nature reviews. Gastroenterology & hepatology · 1 Sept 2026 · Journal Article
Read the brief in JClub
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42469389
Open in JClub
Retraction notice to "Safe use of liver grafts from hepatitis B surface antigen positive donors in liver transplantation" [J Hepatol 61 (2014) 809-815].
Journal of hepatology · 1 Sept 2026 · Retraction Notice
Read the brief in JClub
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42285819
Open in JClub
144 Weeks of bulevirtide monotherapy for chronic hepatitis D: Final and post-treatment results from a phase III randomized trial.
Journal of hepatology · 1 Sept 2026 · Randomized Controlled Trial
Read the brief in JClub
- Open access
- 8 cites
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/41966308
Open in JClub
When biology pushes back: Lessons from HBsAg-targeting therapies in hepatitis delta.
Journal of hepatology · 1 Sept 2026 · Editorial
Read the brief in JClub
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42401242
Open in JClub
Genomics-guided therapy in advanced primary liver cancers: A promising yet methodologically challenging landscape.
Journal of hepatology · 1 Sept 2026 · Letter
Read the brief in JClub
- 1 cites
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42176808
Open in JClub
Hepatitis B.
JAMA · 1 Sept 2026 · Journal Article
Acute and chronic hepatitis B affect millions worldwide, with distinct characteristics and outcomes, emphasizing the importance of early diagnosis and management.
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42418208
Open in JClub
siRNA JNJ-73763989 decreases HBsAg and HDV RNA in NA-treated hepatitis D patients but may cause ALT flares.
Journal of hepatology · 1 Sept 2026 · Randomized Controlled Trial
Read the brief in JClub
- Open access
- 1 cites
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42142631
Open in JClub
Progress and prospects in viral hepatitis elimination.
The lancet. Gastroenterology & hepatology · 1 Sept 2026 · Journal Article
Read the brief in JClub
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42556362
Open in JClub
Precision-cut liver slices as a model for evaluating therapeutic agents against hepatitis B and delta viruses
bioRxiv · 29 Aug 2026 · Preprint
Read the brief in JClub
- Open access
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/10.64898/2025.12.06.692712
Open in JClub
Serum HBsAg cannot distinguish cccDNA activity from integrated HBV DNA expression in chronic hepatitis B virus infection.
Journal of hepatology · 29 Aug 2026 · Journal Article
Read the brief in JClub
- Open access
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42668120
Open in JClub
Advancing functional cure for hepatitis B virus infection.
Journal of hepatology · 27 Aug 2026 · Journal Article
Read the brief in JClub
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42660744
Open in JClub
Liver sinusoid constraints make random search of CD8 T cells for Plasmodium parasites efficient
bioRxiv · 25 Aug 2026 · Preprint
Read the brief in JClub
- Open access
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/10.1101/2025.10.11.681610
Open in JClub
On-demand transarterial chemoembolisation combined with atezolizumab and bevacizumab in patients with untreated hepatocellular carcinoma (TALENTACE): a multicentre, randomised, open-label, phase 3 trial.
The lancet. Gastroenterology & hepatology · 25 Aug 2026 · Journal Article
Read the brief in JClub
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42641632
Open in JClub
Can we de-escalate HCC surveillance after 10 years of HBV suppression on nucleos(t)ide analogues?
Journal of hepatology · 25 Aug 2026 · Editorial
Read the brief in JClub
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42641812
Open in JClub
Optimizing cure following treatment for hepatitis C among people who inject drugs: Where to next?
Journal of hepatology · 25 Aug 2026 · Editorial
Read the brief in JClub
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42641811
Open in JClub
Hepatitis B Surface Antigen Loss and Hepatocellular Carcinoma Surveillance: One Size Does Not Fit All.
Gastroenterology · 17 Aug 2026 · Editorial
Read the brief in JClub
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42607734
Open in JClub
Statistical pitfalls in interpreting zero HCC risk and HBsAg clearance in the long-term PAGE-B cohort.
Journal of hepatology · 14 Aug 2026 · Letter
Read the brief in JClub
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42600944
Open in JClub

Follow this area in the app

Journals this month

All journals →

Moving areas, week to 3 Oct 2026

All research areas →

Read

Moved this week

Latest in Hepatitis B Virus Studies

Browse JClub